New combo therapy for brain metastases shows early promise
NCT ID NCT02015117
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 35 times
Summary
This early-phase trial tests the safety and best dose of the drug trametinib when given with or without whole-brain radiation for people with cancer that has spread to the brain. Trametinib blocks certain enzymes that help cancer cells grow, and radiation uses high-energy X-rays to kill tumor cells. The study aims to find the safest dose and see how well the drug enters the brain, involving 10 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.